Literature DB >> 24367872

Angiosarcoma of the scalp.

Denise Kohen1, Peter Dross1.   

Abstract

Cutaneous angiosarcoma of the scalp is a rare malignant neoplasm of endothelial cells which occurs predominantly in elderly Caucasian males. The etiology is unknown; however the most common association is prior radiation exposure. The diagnosis is often delayed due to misinterpretation for other lesions, including trauma-related bruising and infectious processes such as abscess. Radiologic imaging is non-diagnostic but can be helpful in defining the extent of local disease, as well as distant metastases. Prognosis is poor with a five-year survival rate of less than 30 percent. Treatment guidelines are not well established; however the mainstay is surgical resection with wide margins followed by adjuvant radiation therapy. Prognosis remains poor with a local recurrence rate of greater than 80 percent. Adjuvant chemotherapy is also controversial but may play a role in short term palliation of metastatic or locally advanced disease. Current investigations using molecular targeted therapy are underway with the goal of eliminating systemic side effects.

Entities:  

Mesh:

Year:  2013        PMID: 24367872

Source DB:  PubMed          Journal:  Del Med J        ISSN: 0011-7781


  3 in total

1.  Clinical and dermoscopic features of atypical abdominal brachytherapy-induced angiosarcoma.

Authors:  Beata Bergler-Czop; Karolina Hadasik; Ligia Brzezińska-Wcisło
Journal:  Postepy Dermatol Alergol       Date:  2016-08-16       Impact factor: 1.837

2.  Angiosarcoma of the Scalp: Metastatic Pulmonary Cystic Lesions Initially Misinterpreted as Benign Findings on 18F-FDG PET/CT.

Authors:  Kim Francis Andersen; Elisabeth Albrecht-Beste; Anne Kiil Berthelsen; Annika Loft
Journal:  Diagnostics (Basel)       Date:  2015-12-22

Review 3.  Cutaneous Angiosarcoma: The Possibility of New Treatment Options Especially for Patients with Large Primary Tumor.

Authors:  Yasuhiro Fujisawa; Koji Yoshino; Taku Fujimura; Yoshiyuki Nakamura; Naoko Okiyama; Yosuke Ishitsuka; Rei Watanabe; Manabu Fujimoto
Journal:  Front Oncol       Date:  2018-03-02       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.